Navigation Links
A Broad-Spectrum Antibiotic with Activity Against MRSA and Pseudomonas Aeruginosa Would Earn a Higher Patient Share in the U.S. than in Europe for the Treatment of Hospital-Acquired Pneumonia
Date:3/3/2009

Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's Zosyn/Tazocin) and is priced 50 percent higher than Zosyn/Tazocin would earn a higher patient share in the U.S. (50 percent) than in Europe (30 percent) for the treatment of hospital-acquired pneumonia. This is due to infectious disease specialists in Europe being more sensitive to pricing in their prescribing decisions.

The new report entitled Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics also finds that Merck's Primaxin will remain Decision Resources' proprietary clinical gold standard through 2017. While some therapies in development for hospital-acquired pneumonia hold promise, most have efficacy, safety and tolerability and/or delivery issues when compared to Primaxin.

"Interviewed thought leaders believe that Primaxin has a better spectrum of activity than the benchmark therapy, Zosyn/Tazocin and perceive the agent to be more active against ESBL-producing E. coli and Klebsiella pneumoniae, Pseudomonas and Acinetobacter," stated Hemali Patel, Ph.D., analyst at Decision Resources. "Prescribers we surveyed agree that Primaxin is the most effective antibiotic for hospital-acquired pneumonia."

About the Report

Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Antibiotic Combo Fights Resistant TB
2. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
3. Antibiotic-Resistant Meningitis Reported in U.S.
4. Health experts urge supermarket pharmacies to get smart about free antibiotics
5. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
6. Could carbon dioxide replace antibiotics in surgery?
7. Study shows rise in antibiotic resistant pediatric head and neck infections
8. Free antibiotics: The wrong prescription for cold and flu season
9. E. coli persists against antibiotics through HipA-induced dormancy
10. Antibiotics as Loss Leaders?
11. Preventive Use of Antibiotics Cuts ICU Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: